Navigation Links
Cumberland Pharmaceuticals Announces Joey Jacobs Has Joined Its Board of Directors
Date:1/6/2011

NASHVILLE, Tenn., Jan. 6, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is pleased to announce the addition of Joey Jacobs to its Board of Directors.

A healthcare veteran with more than 30 years of industry experience, Mr. Jacobs is the former Chairman, President and Chief Executive Officer of Nashville-based Psychiatric Solutions, Inc. (PSI), which he co-founded in 1997 and grew into a $2 billion behavioral healthcare system before the company's sale to Universal Health Services in 2010.

Prior to founding PSI, Mr. Jacobs spent 21 years at Hospital Corporation of America (HCA) where he served in various capacities, including President of the company's Tennessee Division.

In addition to serving as Chairman of the Nashville Healthcare Council, he is a director for the Federation of American Hospitals, the National Association of Psychiatric Health Systems and the Monroe Carell, Jr. Children's Hospital at Vanderbilt.

"We are honored to welcome Joey to our Board of Directors," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "Throughout his career, he has maintained a strong focus on quality and growth while creating significant value for stakeholders. His hospital industry perspective, entrepreneurial insight and experience building a successful public healthcare company will be of tremendous value to Cumberland."

Mr. Jacobs' appointment is effective January 1, 2011. He will serve as a Class I Director and hold office until Cumberland's 2011 annual shareholder meeting, at which time the company's Class I Directors will be elected for a term expiring in 2014.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® for the treatment of acetaminophen poisoning, Caldolor®, the first injectable treatment for pain and fever approved in the United States, and Kristalose®, a prescription laxative. Cumberland is dedicated to providing innovative products which improve quality of care for patients. For more information on Cumberland Pharmaceuticals, please visit the Company's website at www.cumberlandpharma.com.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
5. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
6. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... 2017 , ... An August 3rd article on Reuters covers a new University of ... JAMA (the Journal of the American Medical Association). The study found that a lower percentage ... 30, when compared to patients with lower BMIs. At present, weight loss patients must have ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, the leading ... was acquired by Advantage Solutions. The Data Council’s IX-ONE platform is the ... industry’s leading suppliers, brokers, distributors and retailers. The Data Council will become a ...
(Date:8/16/2017)... ... August 16, 2017 , ... In ... They celebrate 30 years in business this year, and they’re marking the milestone ... space to serve their patients. , It stands to reason that, given ...
(Date:8/16/2017)... ... August 16, 2017 , ... Modern Consulting Insurance & ... program. Partnering once again with Boys & Girls Clubs of Greater Kansas City, ... area’s very own American Idol. With all proceeds benefitting local worthy causes, donations ...
(Date:8/16/2017)... ... ... Paul Vitenas, MD, FACS , is honored to announce that he ... the nation’s top physicians, in a variety of specialties. This marks the fourth year ... Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider of information on ...
Breaking Medicine News(10 mins):